Key principle

• Vaginal birth is usually preferred to repeat LSCS in IUFD, because cesarean gives maternal surgical risk without fetal benefit.
• But the previous uterine scar raises the risk of uterine rupture, especially with prostaglandins.
• First establish the type of prior scar. A prior classical/vertical uterine incision, prior rupture, or extensive transfundal surgery makes repeat cesarean more reasonable.

At 28 weeks

Practical approach

1. Confirm IUFD by ultrasound and document fetal presentation, placenta location, amniotic fluid, and estimated fetal size.
2. Review previous LSCS operative note:
   • Low-transverse scar: trial of labor can generally be considered.
   • Classical/T-shaped/unknown but suspected upper-segment scar: do not induce routinely. Discuss repeat cesarean.
3. Baseline assessment
   • Hb, blood group and cross-match, platelet count, coagulation profile including fibrinogen.
   • Check fever, bleeding, rupture of membranes, preeclampsia, abruption, or sepsis.
   • Offer evaluation for cause of fetal death as locally available: placental histology, fetal examination/autopsy or genetic testing, maternal tests guided by history.
4. Induction method for one previous low-transverse LSCS
   • If cervix unfavorable: mechanical cervical ripening with Foley balloon/balloon catheter is preferred.
   • Then use low-dose oxytocin, titrated cautiously, after cervical ripening or if Bishop score is favorable.
   • Avoid routine misoprostol at or beyond 28 weeks in a scarred uterus. It can cause hyperstimulation and scar rupture. If a team considers prostaglandin use because she is exactly 28 weeks and alternatives fail, this requires individualized senior-consultant decision-making, explicit consent, and continuous in-hospital observation, not a routine ward prescription.
   • Avoid excessive oxytocin dosing and avoid uterine tachysystole.
5. Monitoring
   • Maternal pulse, BP, temperature, pain, vaginal bleeding, uterine activity, and signs of scar tenderness/rupture.
   • Continuous fetal monitoring is not relevant after confirmed IUFD, but continuous uterine monitoring and close maternal surveillance are essential.
   • Be ready for urgent surgery and blood transfusion.
6. Third stage
   • Active management with oxytocin.
   • Retained placenta is more common at this gestation. Do not apply forceful traction. Manual removal/evacuation may be required under anesthesia if placenta is retained or bleeding occurs.
7. Counseling
   • Explain the small but serious risk of uterine rupture, hemorrhage, retained placenta, infection, and possible need for emergency laparotomy/hysterectomy.
   • Provide bereavement care, allow family support, discuss seeing/holding the baby if desired, lactation suppression/support, Rh immunoglobulin if Rh-negative and not already sensitized, contraception, and follow-up.

Do not do

• Do not induce at home or in a facility without emergency cesarean capability.
• Do not use high-dose misoprostol routinely in a woman with previous LSCS at 28 weeks.
• Do not perform cesarean solely because the fetus has died, unless there is a maternal indication or an unsafe uterine scar.

Latest guidance: IUFD induction after previous LSCS

Guideline comparison

Practical synthesis for a 28-week IUFD with one previous lower-segment transverse LSCS

1. Confirm scar type from the prior operative note.
   • One previous low-transverse LSCS: induction and planned vaginal birth are usually reasonable.
   • Classical, T/J, high vertical incision, prior uterine rupture, or major transfundal surgery: very high-risk situation. Individualize with senior obstetrician, and repeat cesarean may be appropriate.
2. At exactly 28 weeks, do not automatically use a standard IUFD misoprostol regimen.
   • RCOG explicitly says evidence is insufficient to specify a misoprostol regimen beyond 28+0 weeks with a prior CS.
   • ACOG shifts to TOLAC-type induction protocols after 28 weeks.
   • Therefore, high-dose misoprostol protocols used for unscarred uterus should not be applied routinely.
3. Preferred induction approach where cervix is unfavourable
   • Transcervical Foley balloon catheter for cervical ripening.
   • Then amniotomy when feasible and carefully titrated oxytocin, following local VBAC/TOLAC protocol.
   • Oxytocin use needs senior oversight and close uterine monitoring. There is no fetal heart rate tracing to give early warning of rupture after IUFD, so clinical surveillance is especially important.
4. Avoid or use only under specialist protocol
   • Misoprostol: no universal safe dose can be recommended for a scarred uterus at or after 28 weeks. Follow the hospital's written protocol and consultant decision.
   • Dinoprostone/PGE2: NICE does not recommend a pharmacological method after previous CS because of rupture concerns and lack of evidence.
   • Do not induce outside a unit with immediate theatre, blood products, anesthesia, and senior obstetric cover.
5. Counsel and document
   • Discuss planned vaginal birth versus repeat cesarean, including uterine rupture, hemorrhage, infection, retained placenta, possible laparotomy/hysterectomy, and future reproductive risks.
   • Perform maternal assessment, including CBC, group and cross-match, and coagulation testing including fibrinogen if prolonged retention, abruption, sepsis, or bleeding is suspected.
   • Investigate cause of death with placental histology, genetic testing and postmortem examination where consented.

Important nuance

IUFD Induction After Previous LSCS

Quick Reference - Hospital/Senior Obstetrician Use

1. Core principles

• Vaginal birth is preferred for most women with IUFD because cesarean provides no fetal benefit and adds maternal operative and future pregnancy risk.
• Previous LSCS increases risk of uterine rupture during induction.
• Conduct induction only in a unit with immediate access to theater, anesthesia, blood products, and senior obstetric support.
• Confirm fetal death by ultrasound and review the prior cesarean operative note.

2. Risk stratify scar

3. At 28 weeks or later

1. Assess Bishop score and presentation.
2. If cervix unfavorable, use a transcervical Foley balloon catheter for ripening.
3. Consider amniotomy when feasible.
4. Use carefully titrated oxytocin according to the local VBAC/TOLAC protocol.
5. Closely monitor contractions and maternal condition.

4. Prostaglandins and misoprostol

• Do not apply routine high-dose IUFD misoprostol protocols to a scarred uterus at or after 28 weeks.
• RCOG 2025 states there is insufficient evidence for a specific misoprostol regimen beyond 28+0 weeks in women with previous cesarean or transmural uterine scar.
• NICE does not recommend prostaglandin induction after previous CS because of limited evidence and concern about uterine rupture.
• Any consideration of misoprostol or dinoprostone must be an individualized consultant decision under a local written protocol.

5. Maternal assessment before induction

• Confirm IUFD and gestational age.
• Review obstetric history, scar type, placental location, and contraindications to vaginal birth.
• CBC, blood group and cross-match.
• Coagulation screen and fibrinogen if prolonged fetal retention, bleeding, abruption, sepsis, or clinical concern.
• Evaluate for preeclampsia, infection, rupture of membranes, and placental abruption.
• Discuss investigations: placental histology, fetal examination/autopsy, and genetic testing.

6. Monitor for uterine rupture

• Sudden severe or atypical abdominal pain
• Scar tenderness
• Vaginal bleeding
• Maternal tachycardia, hypotension, or collapse
• Hematuria
• Loss of uterine tone or abnormal uterine contour
• Failure to progress or sudden cessation of contractions

7. Third stage and aftercare

• Active management of third stage with oxytocin.
• Anticipate retained placenta and postpartum hemorrhage.
• Avoid forceful cord traction.
• Give anti-D immunoglobulin if RhD-negative and not sensitized, according to local protocol.
• Provide analgesia, bereavement support, lactation advice/suppression if desired, contraception counseling, and follow-up to discuss investigation results.

Bottom line

RCOG

ACOG/SMFM

NICE

Latest evidence: Foley balloon versus misoprostol after previous LSCS

Bottom line for IUFD with previous LSCS

Key recent evidence

1. Second-trimester mifepristone-misoprostol after prior CS
   The most relevant modern systematic review/meta-analysis included 22 studies and pregnancies at 14-28 weeks, including fetal death management. Uterine rupture occurred in 10/874 (1.1%) with a prior cesarean versus 2/6,244 (0.01%) without prior cesarean. Three of 12 reported ruptures required hysterectomy.
   Henkel et al., 2023 systematic review [PMID: 37884011]
2. Foley versus oral misoprostol in general induction populations
   An individual-participant-data meta-analysis of four RCTs, 2,815 participants, found Foley had a slightly lower chance of vaginal birth than oral misoprostol: RR 0.95, 95% CI 0.91-0.99. Composite adverse maternal outcomes did not differ. However, this is not evidence that misoprostol is safe after previous LSCS, because it was based on viable singleton induction populations rather than the specific IUFD-plus-scar scenario.
   Kemper et al., 2021 IPD meta-analysis [PMID: 33258514]
3. NICE evidence review, exact clinical question
   NICE reviewed induction after IUFD in women with a previous cesarean and found no eligible direct evidence to establish the safest method. It therefore emphasizes counseling about rupture, the suitability of mechanical methods, and the fact that dinoprostone and misoprostol product labeling contraindicates use in women with a uterine scar.
   NICE Evidence Review D

Guideline-concordant implication at 28 weeks

• Foley balloon is the better-supported cervical-ripening choice if the cervix is unfavorable.
• Follow with amniotomy when appropriate and cautiously titrated oxytocin under local TOLAC/VBAC protocol.
• Do not use a routine high-dose misoprostol IUFD regimen in a scarred uterus.
• If misoprostol is considered near the 24-28-week boundary, it should be a consultant-led, individualized decision under a local protocol, with documented counseling about rupture risk.
• Induction must occur where emergency laparotomy, anesthesia, transfusion, and senior obstetric care are immediately available.